Barbara J. Brandhuber
Array BioPharma (United States)(US)Loxo Oncology at Lilly (United States)(US)
Publications by Year
Research Areas
Melanoma and MAPK Pathways, PI3K/AKT/mTOR signaling in cancer, Cancer Mechanisms and Therapy, Immune Response and Inflammation, Lung Cancer Treatments and Mutations
Most-Cited Works
- → RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth(2010)1,616 cited
- → Biological Characterization of ARRY-142886 (AZD6244), a Potent, Highly Selective Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor(2007)582 cited
- → Interleukin-1 (IL-1) receptor antagonist binds to the 80-kDa IL-1 receptor but does not initiate IL-1 signal transduction(1991)454 cited
- → Selective RET kinase inhibition for patients with RET-altered cancers(2018)426 cited
- → A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion–Positive Solid Tumors(2017)425 cited
- → Crystal Structure of Human AKT1 with an Allosteric Inhibitor Reveals a New Mode of Kinase Inhibition(2010)320 cited